The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
Open accessAbstract
Overexpression of proinflammatory, type 1 cytokines has been demonstrated in psoriasis and is believed to be of pathophysiological importance. IL-10 is a type 2 cytokine with major impact on immunoregulation, since it inhibits type 1/proinflammatory cytokine formation. Therefore, we investigated its role in psoriasis. We found a relative deficiency in cutaneous IL-10 mRNA expression compared with other inflammatory dermatoses. Interestingly, patients during established antipsoriatic therapy showed higher IL-10 mRNA expression of peripheral blood mononuclear cells than patients before therapy. This suggested that IL-10 may have antipsoriatic capacity. Therefore, we performed a phase 2 pilot trial with subcutaneous IL-10 administration (8 microg/kg/d) over 24 d in three patients. Clinical efficiency measured by objective and subjective parameters was found. Immunosuppressive effects (depressed monocytic HLA-DR expression, TNF-alpha and IL-12 secretion capacity, IL-12 plasma levels, and responsiveness to recall antigens) as well as a shift toward a type 2 cytokine pattern (increasing proportion of IL-4, IL-5, and IL-10 producing T cells, selective increase in IgE serum levels) were observed. Remarkably, IL-10 administration also enhanced the intracutaneous IL-10 mRNA expression. Our investigations demonstrate the major importance of IL-10 in psoriasis and show that IL-10 administration represents a new therapeutic approach. This is the first report on IL-10 therapy for cutaneous disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Wegmann, T. G., Lin, H., Guilbert, L., & Mosmann, T. R. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90235-d · Cited by 2,852
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., & Trinchieri, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1041 · Cited by 1,385
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Self-citationvan Deventer, S., Elson, C., & Fedorak, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9247454 · Cited by 486
Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
ETTEHADI, P., GREAVES, M. W., WALLACH, D., ADERKA, D., & CAMP, R. D. R. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06244.x · Cited by 481
T Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset
Schlaak, J. F., Buslau, M., Jochum, W., Hermann, E., Girndt, M., Gallati, H., Büschenfelde, K.-H. M. Z., & Fleischer, B. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371752 · Cited by 455
Uyemura, K., Yamamura, M., Fivenson, D. F., Modlin, R. L., & Nickoloff, B. J. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371679 · Cited by 450
Dermal injection of immunocytes induces psoriasis.
Wrone-Smith, T., & Nickoloff, B. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118989 · Cited by 439
Chernoff, A. E., Granowitz, E. V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J. B., Kennedy, J. S., Rabson, A. R., Wolff, S. M., & Dinarello, C. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.10.5492 · Cited by 418
Biology of human TH1 and TH2 cells
Romagnani, S. (1995) · Journal of Clinical Immunology · doi:10.1007/bf01543103 · Cited by 406
Rivas, J. M., & Ullrich, S. E. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.12.3865 · Cited by 396
Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
Volk, H. D., Reinke, P., Krausch, D., Zuckermann, H., Asadullah, K., Müller, J. M., Döcke, W. D., & Kox, W. J. (1996) · Intensive Care Medicine · doi:10.1007/bf01743727 · Cited by 361
Self-citationThe Cytokine Network in Psoriasis
Nickoloff, B. J. (1991) · Archives of Dermatology · doi:10.1001/archderm.127.6.871 · Cited by 344
Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytes
Valdimarsson, H., Bake, B. S., Jónsdótdr, I., & Fry, L. (1986) · Immunology Today · doi:10.1016/0167-5699(86)90005-8 · Cited by 328
Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs
Platzer, C., Meisel, C., Vogt, K., Platzer, M., & Volk, H.-D. (1995) · International Immunology · doi:10.1093/intimm/7.4.517 · Cited by 317
Self-citationAntipsoriatic effect of fumaric acid derivatives
Altmeyer, P. J., Mattlies, U., Pawlak, F., Hoffmann, K., Frosch, P. J., Ruppert, P., Wassilew, S. W., Horn, T., Kreysel, H. W., Lutz, G., et al. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70121-0 · Cited by 300
Ohmen, J. D., Hanifin, J. M., Nickoloff, B. J., Rea, T. H., Wyzykowski, R., Kim, J., Jullien, D., McHugh, T., Nassif, A. S., & Chan, S. C. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.4.1956 · Cited by 274
Role of Growth Factors, Cytokines, and Their Receptors in the Pathogenesis of Psoriasis
Krueger, J. G., Krane, J. F., Carter, D. M., & Gottlieb, A. B. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12876121 · Cited by 242
Drugs in exacerbation of psoriasis
Abel, E. A., DiCicco, L. M., Orenberg, E. K., Fraki, J. E., & Farber, E. M. (1986) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(86)70265-x · Cited by 231
de Jong, R., Bezemer, A. C., Zomerdijk, T. P. L., van de Pouw‐Kraan, T., Ottenhoff, T. H. M., & Nibbering, P. H. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260916 · Cited by 226
Kang, K., Hammerberg, C., Meunier, L., & Cooper, K. D. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.11.5256 · Cited by 190
Jenkins, J. K., Malyak, M., & Arend, W. P. (1994) · PubMed · Cited by 181
Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro.
Enk, C. D., Sredni, D., Blauvelt, A., & Katz, S. I. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.9.4851 · Cited by 177
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
Jegasothy, B. V. (1992) · Archives of Dermatology · doi:10.1001/archderm.128.6.781 · Cited by 166
Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., & Nickoloff, B. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2668 · Cited by 156
Asadullah, K., Döcke, W., Haeuβler, A., Sterry, W., & Volk, H. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12330869 · Cited by 130
Self-citationPSORIASIS AND PREGNANCY: HORMONE AND IMMUNE SYSTEM INTERACTION
Boyd, A. S., Morris, L. F., Phillips, C. M., & Menter, M. A. (1996) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1996.tb01632.x · Cited by 129
IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy
Lemster, B. H., Carroll, P. B., Rilo, H., Johnson, N., Nikaein, A., & Thomson, A. W. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05525.x · Cited by 103
Bécherel, P., Goff, L. L., Ktorza, S., Ouaaz, F., Mencia‐Huerta, J., Dugas, B., Debré, P., Mossalayi, M. D., & Arock, M. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251042 · Cited by 74
Asadullah, K., Schmid, H., Friedrich, M., Randow, F., Volk, H., Sterry, W., & Döcke, W. (1997) · Archives of Dermatological Research · doi:10.1007/s004030050251 · Cited by 73
Self-citationKristensen, M., Deleuran, B. W., Eedy, D. J., LDMANN, M. F., BREATHNACH, S. M., & Brennan, F. M. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb00446.x · Cited by 67
Cytokine expression in psoriatic skin lesions during PUVA therapy
Olaniran, A. K., Baker, B. S., Paige, D. G., Garioch, J., Powles, A. V., & Fry, L. (1996) · Archives of Dermatological Research · doi:10.1007/bf02505228 · Cited by 49
Mussi, A., Bonifati, C., Carducci, M., Viola, M., Tomaselli, R., Sacerdoti, G., Fazio, M., & Ameglio, F. (1994) · PubMed · Cited by 37
Ockenfels, H. M., Wagner, S. N., Keim-Maas, C., Funk, R., Nussbaum, G., & Goos, M. (1996) · Archives of Dermatological Research · doi:10.1007/bf02505220 · Cited by 36
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.09.002 · Cited by 977
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Self-citationEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Metadata
- Authors
- Asadullah, K., Sterry, W., Stephanek, K., Jasulaitis, D., Leupold, M., Audring, H., Volk, H. D., & Döcke, W. D.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 783-794
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2089323062
- Cited by
- 415
- References
- 37
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.